Skip to main content
Erschienen in: Drugs 18/2006

01.12.2006 | Therapy In Practice

An Overview of the Diagnosis and Treatment of Erectile Dysfunction

verfasst von: Dr Sivaprakasam Sivalingam, Hashim Hashim, Hartwig Schwaibold

Erschienen in: Drugs | Ausgabe 18/2006

Einloggen, um Zugang zu erhalten

Abstract

Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fuelled the increase in treatment-seeking behaviour among men.
Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED.
Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting ‘the couple’ and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist.
The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined ‘step-ladder’ escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.
Literatur
1.
Zurück zum Zitat The Second International Consultation on Dysfunction. Sexual Medicine: Sexual Dysfunctions in Men and Women. 2004 Jun 28-Jul 1; Paris The Second International Consultation on Dysfunction. Sexual Medicine: Sexual Dysfunctions in Men and Women. 2004 Jun 28-Jul 1; Paris
2.
Zurück zum Zitat Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460–3PubMedCrossRef Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460–3PubMedCrossRef
3.
Zurück zum Zitat Moreira Jr ED, Lbo CF, Diament A, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431–6PubMedCrossRef Moreira Jr ED, Lbo CF, Diament A, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431–6PubMedCrossRef
4.
Zurück zum Zitat Schouten BW, Bosch JL, Bernsen RM, et al. Incidence of clinical relevant erectile dysfunction (ED) and ED by two other common definitions: strong effect of definition and bias by duration follow-up. Int J Impot Res 2005; 17: 58–62PubMedCrossRef Schouten BW, Bosch JL, Bernsen RM, et al. Incidence of clinical relevant erectile dysfunction (ED) and ED by two other common definitions: strong effect of definition and bias by duration follow-up. Int J Impot Res 2005; 17: 58–62PubMedCrossRef
5.
Zurück zum Zitat Kinsey AC, Pomeroy WB, Martin CE. Sexual behaviour of the human male. Philadelphia (PA): WB Saunders and Co, 1948 Kinsey AC, Pomeroy WB, Martin CE. Sexual behaviour of the human male. Philadelphia (PA): WB Saunders and Co, 1948
6.
Zurück zum Zitat Shabsig R, Alexandre A, Bay Nielsen H, et al. Economic aspects of erectile dysfunction [abstract]. 1st International Consultation on Erectile Dysfunction; 1999 Jul 1–3; Paris. Plymouth: Plymbridge Distributors Ltd Shabsig R, Alexandre A, Bay Nielsen H, et al. Economic aspects of erectile dysfunction [abstract]. 1st International Consultation on Erectile Dysfunction; 1999 Jul 1–3; Paris. Plymouth: Plymbridge Distributors Ltd
7.
Zurück zum Zitat Sexual Dysfunction Therapeutics. A market overview and therapeutics analysis 2002. San Mateo (CA): Frontline Strategic Consultation Inc., 2002 Sexual Dysfunction Therapeutics. A market overview and therapeutics analysis 2002. San Mateo (CA): Frontline Strategic Consultation Inc., 2002
8.
Zurück zum Zitat British National Formulary. No. 51 (Mar 2006). London: BMJ Publishing Group Ltd, 2006 British National Formulary. No. 51 (Mar 2006). London: BMJ Publishing Group Ltd, 2006
9.
Zurück zum Zitat Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Imp Res 1999; 11: 141–4CrossRef Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Imp Res 1999; 11: 141–4CrossRef
11.
Zurück zum Zitat Hengeveld MW. Erectile disorder: a psychosexological review. In: Jonas U, Thon WF, Stief CG, editors. Erectile dysfunction. Berlin: Springer Verlag, 1991 Hengeveld MW. Erectile disorder: a psychosexological review. In: Jonas U, Thon WF, Stief CG, editors. Erectile dysfunction. Berlin: Springer Verlag, 1991
12.
Zurück zum Zitat O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 782–3 O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 782–3
13.
Zurück zum Zitat Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30PubMedCrossRef Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30PubMedCrossRef
14.
Zurück zum Zitat Althof SE, Corty EW, Morales SB, et al. Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793–9PubMedCrossRef Althof SE, Corty EW, Morales SB, et al. Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793–9PubMedCrossRef
15.
Zurück zum Zitat Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–42PubMedCrossRef Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–42PubMedCrossRef
16.
Zurück zum Zitat Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997; 9: 115–21PubMedCrossRef Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997; 9: 115–21PubMedCrossRef
17.
Zurück zum Zitat Ballard SA, Gingell JC, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum in vitro and on the activities of cyclic nucleotide phosphodiesterase isozyme. J Urol 1998; 159: 2164–71PubMedCrossRef Ballard SA, Gingell JC, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum in vitro and on the activities of cyclic nucleotide phosphodiesterase isozyme. J Urol 1998; 159: 2164–71PubMedCrossRef
18.
Zurück zum Zitat Baxendale RW, Smith EJ, Stanley M, et al. Selectivity of sildenafil citrate and other phosphodiesterases type 5 inhibitors against phosphodiesterases types 7–11 [abstract]. J Clin Pharmacol 2001; 41: 1015 Baxendale RW, Smith EJ, Stanley M, et al. Selectivity of sildenafil citrate and other phosphodiesterases type 5 inhibitors against phosphodiesterases types 7–11 [abstract]. J Clin Pharmacol 2001; 41: 1015
19.
Zurück zum Zitat Saenz de Tejada I, Angula J, Cuevas P, et al. The phosphodiesterase inhibitor selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–90PubMedCrossRef Saenz de Tejada I, Angula J, Cuevas P, et al. The phosphodiesterase inhibitor selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–90PubMedCrossRef
20.
Zurück zum Zitat Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J 2002; 4 Suppl. H: H7–12 Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J 2002; 4 Suppl. H: H7–12
23.
Zurück zum Zitat Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397–404PubMedCrossRef Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397–404PubMedCrossRef
24.
Zurück zum Zitat Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 845–1039CrossRef Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 845–1039CrossRef
25.
Zurück zum Zitat Zelefsky MJ, Mckee AB, Lee H, et al. Efficacy of sildenafil in patients with erectile dysfunction after radiotherapy of the prostate. Urology 1999; 53: 775–8PubMedCrossRef Zelefsky MJ, Mckee AB, Lee H, et al. Efficacy of sildenafil in patients with erectile dysfunction after radiotherapy of the prostate. Urology 1999; 53: 775–8PubMedCrossRef
26.
Zurück zum Zitat Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112–6PubMedCrossRef Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112–6PubMedCrossRef
27.
Zurück zum Zitat Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5PubMedCrossRef Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5PubMedCrossRef
28.
Zurück zum Zitat Sadovsky R, Miller T, Moskowitz M, et al. Three year update of sildenafil citrate (Viagra™) efficacy and safety. Int J Clin Prac 2001; 55: 115–28 Sadovsky R, Miller T, Moskowitz M, et al. Three year update of sildenafil citrate (Viagra™) efficacy and safety. Int J Clin Prac 2001; 55: 115–28
29.
Zurück zum Zitat Morales A, Gingell GC, Collins M, et al. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–73PubMedCrossRef Morales A, Gingell GC, Collins M, et al. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–73PubMedCrossRef
30.
Zurück zum Zitat Arruda Olson A, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002 287: 719–25PubMedCrossRef Arruda Olson A, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002 287: 719–25PubMedCrossRef
31.
Zurück zum Zitat Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 2000; 342: 1622–6CrossRef Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 2000; 342: 1622–6CrossRef
32.
33.
Zurück zum Zitat Hellstrom WG, Gittleman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind placebo controlled trial. J Androl 2002; 23: 763–72PubMed Hellstrom WG, Gittleman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind placebo controlled trial. J Androl 2002; 23: 763–72PubMed
34.
Zurück zum Zitat Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor improves erectile function in patients with diabetes mellitus. Proc Am Diabetic Assoc Jun 2001 Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor improves erectile function in patients with diabetes mellitus. Proc Am Diabetic Assoc Jun 2001
35.
Zurück zum Zitat Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278–83PubMedCrossRef Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278–83PubMedCrossRef
37.
Zurück zum Zitat Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent highly selective phosphodiesterase inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardio 2002; 40: 2006–12CrossRef Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent highly selective phosphodiesterase inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardio 2002; 40: 2006–12CrossRef
38.
Zurück zum Zitat Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1322–6CrossRef Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1322–6CrossRef
39.
Zurück zum Zitat Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled trial. Urology 2003; 62: 121–5PubMedCrossRef Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled trial. Urology 2003; 62: 121–5PubMedCrossRef
40.
Zurück zum Zitat Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–8PubMedCrossRef Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–8PubMedCrossRef
41.
Zurück zum Zitat Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacokinetic study. World J Urol 2001; 19: 32–9PubMedCrossRef Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacokinetic study. World J Urol 2001; 19: 32–9PubMedCrossRef
42.
Zurück zum Zitat Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no deleterious effect on spermatogenesis or reproductive hormones. J Urol 2003; 170: 887–91PubMedCrossRef Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no deleterious effect on spermatogenesis or reproductive hormones. J Urol 2003; 170: 887–91PubMedCrossRef
43.
Zurück zum Zitat Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile function in men with diabetes. Diabetes Care 2002; 25: 2159–64PubMedCrossRef Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile function in men with diabetes. Diabetes Care 2002; 25: 2159–64PubMedCrossRef
44.
Zurück zum Zitat Patterson D, Kloner R, Effron MB, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60: 459–68PubMedCrossRef Patterson D, Kloner R, Effron MB, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60: 459–68PubMedCrossRef
45.
Zurück zum Zitat Stroberg P, Yu CC, Su CC, et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724–37PubMedCrossRef Stroberg P, Yu CC, Su CC, et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724–37PubMedCrossRef
46.
Zurück zum Zitat von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomised, double-blind, cross-over study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507CrossRef von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomised, double-blind, cross-over study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507CrossRef
47.
Zurück zum Zitat Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomised, double blind, cross-over study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709–23PubMedCrossRef Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomised, double blind, cross-over study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709–23PubMedCrossRef
48.
Zurück zum Zitat Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitor for erectile dysfunction. Eur Urol 2006; 49: 30–7PubMedCrossRef Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitor for erectile dysfunction. Eur Urol 2006; 49: 30–7PubMedCrossRef
49.
Zurück zum Zitat Eardley I, Mirone V, Montorsi F, et al. An open label, multicentre, randomised, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–32PubMedCrossRef Eardley I, Mirone V, Montorsi F, et al. An open label, multicentre, randomised, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–32PubMedCrossRef
50.
Zurück zum Zitat Dula E, Bukofzer S, Perdol R, et al. Double blind, crossover comparison of 3mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–64PubMedCrossRef Dula E, Bukofzer S, Perdol R, et al. Double blind, crossover comparison of 3mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–64PubMedCrossRef
51.
Zurück zum Zitat Heaton JP. Key issues from clinical trial of apomorphine SL. Int J Impot Res 2000; Suppl. 4: S67–73 Heaton JP. Key issues from clinical trial of apomorphine SL. Int J Impot Res 2000; Suppl. 4: S67–73
52.
Zurück zum Zitat Eardley I, Wright P, Macdonagh R, et al. An open label, randomised, flexible dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271–5PubMedCrossRef Eardley I, Wright P, Macdonagh R, et al. An open label, randomised, flexible dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271–5PubMedCrossRef
53.
Zurück zum Zitat Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 274–9 Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 274–9
54.
Zurück zum Zitat Junemann KP, Manning M, Krautschik A, et al. 15 years of injection therapy in erectile dysfunction: a review [abstract]. Int J Impot Res 1996; 8: A60 Junemann KP, Manning M, Krautschik A, et al. 15 years of injection therapy in erectile dysfunction: a review [abstract]. Int J Impot Res 1996; 8: A60
55.
Zurück zum Zitat Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly, nonpsychogenic erectile dysfunction with vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo controlled study. BJU Int 1999; 83: 274–9PubMedCrossRef Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly, nonpsychogenic erectile dysfunction with vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo controlled study. BJU Int 1999; 83: 274–9PubMedCrossRef
57.
Zurück zum Zitat Padma-Nathan H, Hellstrom W, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Eng J Med 1997; 336: 1–7PubMedCrossRef Padma-Nathan H, Hellstrom W, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Eng J Med 1997; 336: 1–7PubMedCrossRef
58.
Zurück zum Zitat Williams G, Abbou CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction and their partners. Br J Urol 1998; 82: 847–54PubMedCrossRef Williams G, Abbou CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction and their partners. Br J Urol 1998; 82: 847–54PubMedCrossRef
59.
Zurück zum Zitat Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomised, crossover multicentre study. Urology 2000; 55: 109–13PubMedCrossRef Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomised, crossover multicentre study. Urology 2000; 55: 109–13PubMedCrossRef
60.
Zurück zum Zitat Gauthier A, Rutchik DS, Winters CJ, et al. Relative efficacy of sildenafil compared to other treatment options for erectile dysfunction. South Med J 2000; 93: 962–5PubMed Gauthier A, Rutchik DS, Winters CJ, et al. Relative efficacy of sildenafil compared to other treatment options for erectile dysfunction. South Med J 2000; 93: 962–5PubMed
61.
Zurück zum Zitat Meyhoff H, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitrogylcerine. Br J Urol 1992; 69: 88–90PubMedCrossRef Meyhoff H, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitrogylcerine. Br J Urol 1992; 69: 88–90PubMedCrossRef
62.
Zurück zum Zitat Goldstein I, Payton TR, Schecter PJ. A double blind, placebo controlled, efficacy and safety study of topical gel formulation of 1 % alprostadil (Topiglan™) for in-office treatment of erectile dysfunction. Urology 2001; 57: 301–4PubMedCrossRef Goldstein I, Payton TR, Schecter PJ. A double blind, placebo controlled, efficacy and safety study of topical gel formulation of 1 % alprostadil (Topiglan™) for in-office treatment of erectile dysfunction. Urology 2001; 57: 301–4PubMedCrossRef
63.
Zurück zum Zitat Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate and co-dergocrine mesylate. BMJ 1996; 312: 1512–5PubMedCrossRef Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate and co-dergocrine mesylate. BMJ 1996; 312: 1512–5PubMedCrossRef
64.
Zurück zum Zitat Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–7PubMedCrossRef Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–7PubMedCrossRef
65.
Zurück zum Zitat Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endcrinol Metab 1990; 71: 963–9CrossRef Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endcrinol Metab 1990; 71: 963–9CrossRef
66.
67.
Zurück zum Zitat Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61–8PubMedCrossRef Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61–8PubMedCrossRef
68.
Zurück zum Zitat Rosenthal BD, May NR, Metro MJ, et al. Adjuvant use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571–4PubMedCrossRef Rosenthal BD, May NR, Metro MJ, et al. Adjuvant use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571–4PubMedCrossRef
69.
Zurück zum Zitat Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 4: 559–4CrossRef Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 4: 559–4CrossRef
70.
Zurück zum Zitat Shabsigh R, Kaufman JM, Steidle C, et al. Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–63PubMedCrossRef Shabsigh R, Kaufman JM, Steidle C, et al. Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–63PubMedCrossRef
71.
Zurück zum Zitat American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients. Endocr Pract 2002; 8: 439-56 American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients. Endocr Pract 2002; 8: 439-56
72.
Zurück zum Zitat Cookson MS, Nadig PW. Long-term results with vacuum constriction devices. J Urol 1993; 149: 290–4PubMed Cookson MS, Nadig PW. Long-term results with vacuum constriction devices. J Urol 1993; 149: 290–4PubMed
73.
Zurück zum Zitat Gilbert HW, Gingell JC. Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81–3PubMedCrossRef Gilbert HW, Gingell JC. Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81–3PubMedCrossRef
74.
Zurück zum Zitat Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with Ambicor inflatable penile prosthesis: results of a two center study. J Urol 2001; 166: 932–7PubMedCrossRef Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with Ambicor inflatable penile prosthesis: results of a two center study. J Urol 2001; 166: 932–7PubMedCrossRef
75.
Zurück zum Zitat Montorsi F, Rigatti P, Carmignani G, et al. AMS three piece inflatable implants for erectile dysfunction: a long-term multiinstitutional trial studying 200 consecutive patients. Eur Urol 2000; 35: 50–5CrossRef Montorsi F, Rigatti P, Carmignani G, et al. AMS three piece inflatable implants for erectile dysfunction: a long-term multiinstitutional trial studying 200 consecutive patients. Eur Urol 2000; 35: 50–5CrossRef
76.
Zurück zum Zitat Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700 CX inflatable penile prosthesis: results of long-term multi-center study. J Urol 2000; 164: 376–80PubMedCrossRef Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700 CX inflatable penile prosthesis: results of long-term multi-center study. J Urol 2000; 164: 376–80PubMedCrossRef
77.
Zurück zum Zitat Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001; 13: 326–8PubMedCrossRef Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001; 13: 326–8PubMedCrossRef
78.
Zurück zum Zitat Wilson SK, Delk JR, Henry GD. Short term follow for enhanced American Medical Systems 700 CX prosthesis [abstract no. 600A]. J Urol 2002; 167 Suppl. 4 Wilson SK, Delk JR, Henry GD. Short term follow for enhanced American Medical Systems 700 CX prosthesis [abstract no. 600A]. J Urol 2002; 167 Suppl. 4
79.
Zurück zum Zitat Wolter CE, Hellstrom WJ. The hydrophilic coated inflatable penile prosthesis: 1 year experience. J Sex Med 2004; 1: 221–4PubMedCrossRef Wolter CE, Hellstrom WJ. The hydrophilic coated inflatable penile prosthesis: 1 year experience. J Sex Med 2004; 1: 221–4PubMedCrossRef
80.
Zurück zum Zitat Mulcahy JJ. Long-term experience with salvage of infected penile prosthesis. J Urol 2000; 163: 481–2PubMedCrossRef Mulcahy JJ. Long-term experience with salvage of infected penile prosthesis. J Urol 2000; 163: 481–2PubMedCrossRef
81.
Zurück zum Zitat Fishman IJ, Scott FB, Selim A, et al. The rescue procedure: an alternative for managing infected penile prosthesis. Contemp Urol 1997; 11: 73–80 Fishman IJ, Scott FB, Selim A, et al. The rescue procedure: an alternative for managing infected penile prosthesis. Contemp Urol 1997; 11: 73–80
82.
Zurück zum Zitat Kaufman JM, Kaufman JL, Borges FD. Immediate salvage procedure for infected penile prosthesis. J Urol 1998; 159: 816–9PubMedCrossRef Kaufman JM, Kaufman JL, Borges FD. Immediate salvage procedure for infected penile prosthesis. J Urol 1998; 159: 816–9PubMedCrossRef
83.
Zurück zum Zitat Sharaby JS, Benet AE, Melman A. Revascularisation: a five year follow-up study [abstract]. J Urol 1995; 153: 369A Sharaby JS, Benet AE, Melman A. Revascularisation: a five year follow-up study [abstract]. J Urol 1995; 153: 369A
84.
Zurück zum Zitat Konnak JW, Ohl DA. Microsurgical penile revascularisation using central corporeal penile artery. J Urol 1989; 142: 305–8PubMed Konnak JW, Ohl DA. Microsurgical penile revascularisation using central corporeal penile artery. J Urol 1989; 142: 305–8PubMed
85.
86.
Zurück zum Zitat Rao DS, Donatucci CF. Vasculogenic impotence: arterial and venous surgery. Urol Clin NA 2001; 22: 309–19CrossRef Rao DS, Donatucci CF. Vasculogenic impotence: arterial and venous surgery. Urol Clin NA 2001; 22: 309–19CrossRef
87.
Zurück zum Zitat Berradinucci C, Morales A, Heaton JP, et al. Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1997; 47: 88–92CrossRef Berradinucci C, Morales A, Heaton JP, et al. Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1997; 47: 88–92CrossRef
88.
Zurück zum Zitat Schultheiss D, Truss MC, Becker AJ, et al. Long-term results following dorsal penile ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205–9PubMedCrossRef Schultheiss D, Truss MC, Becker AJ, et al. Long-term results following dorsal penile ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205–9PubMedCrossRef
89.
Zurück zum Zitat Lukkarinen O, Tontilla P, Hellstrom P, et al. Non prosthetic surgery in the treatment of erectile dysfunction. Scan J Urol Nephrol 1997; 32: 42–6 Lukkarinen O, Tontilla P, Hellstrom P, et al. Non prosthetic surgery in the treatment of erectile dysfunction. Scan J Urol Nephrol 1997; 32: 42–6
90.
Zurück zum Zitat Arjona M, Osteros R, Zarca M, et al. Percutaneous embolisation for erectile dysfunction due to venous leakage: prognostic factors for good therapeutic results. Eur Urol 2001; 39: 15–9 Arjona M, Osteros R, Zarca M, et al. Percutaneous embolisation for erectile dysfunction due to venous leakage: prognostic factors for good therapeutic results. Eur Urol 2001; 39: 15–9
91.
Zurück zum Zitat Miwa Y, Shioyama R, Itou Y, et al. Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76–9PubMedCrossRef Miwa Y, Shioyama R, Itou Y, et al. Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76–9PubMedCrossRef
92.
Zurück zum Zitat Peskircioglu L, Tekin I, Boyvat F, et al. Embolisation of the deep dorsal vein for the treatment of erectile impotence due to veno-occlusive dysfunction. J Urol 2000; 163: 472–5PubMedCrossRef Peskircioglu L, Tekin I, Boyvat F, et al. Embolisation of the deep dorsal vein for the treatment of erectile impotence due to veno-occlusive dysfunction. J Urol 2000; 163: 472–5PubMedCrossRef
93.
Zurück zum Zitat Alossini G, Ficarra V, Cavalleri S, et al. Long-term results of veno-occlusive percutaneous treatment of erectile disorders of venous origin. Arch Ital Androl 1998; 70: 203–9 Alossini G, Ficarra V, Cavalleri S, et al. Long-term results of veno-occlusive percutaneous treatment of erectile disorders of venous origin. Arch Ital Androl 1998; 70: 203–9
94.
Zurück zum Zitat Martinez Portillo FJ, Junemann KP, Sohn M. Surgical therapy of erectile dysfunction: current status [in German]. Urologe A 2003; 42: 1337–44PubMedCrossRef Martinez Portillo FJ, Junemann KP, Sohn M. Surgical therapy of erectile dysfunction: current status [in German]. Urologe A 2003; 42: 1337–44PubMedCrossRef
95.
Zurück zum Zitat Dorey G, Speakman MJ, Feneley RCL, et al. Pelvic floor exercises for erectile dysfunction. BJU Int 2005; 96: 595–7PubMedCrossRef Dorey G, Speakman MJ, Feneley RCL, et al. Pelvic floor exercises for erectile dysfunction. BJU Int 2005; 96: 595–7PubMedCrossRef
96.
Zurück zum Zitat Masters WH, Johnson VE. Human sexual inadequacy. London: Churchill, 1970 Masters WH, Johnson VE. Human sexual inadequacy. London: Churchill, 1970
97.
Zurück zum Zitat Hawton K, Catalan J. Prognostic factors in sex therapy. Behav Sex Ther 1986; 24: 377–85 Hawton K, Catalan J. Prognostic factors in sex therapy. Behav Sex Ther 1986; 24: 377–85
98.
Zurück zum Zitat Barnes P. Role of sex therapy in the management of ED. In: Kirby RS, Carson C, Webster GD, editors. Impotence diagnosis and management of male ED. Oxford: Butterworth-Heinemann, 1991 Barnes P. Role of sex therapy in the management of ED. In: Kirby RS, Carson C, Webster GD, editors. Impotence diagnosis and management of male ED. Oxford: Butterworth-Heinemann, 1991
Metadaten
Titel
An Overview of the Diagnosis and Treatment of Erectile Dysfunction
verfasst von
Dr Sivaprakasam Sivalingam
Hashim Hashim
Hartwig Schwaibold
Publikationsdatum
01.12.2006
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 18/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200666180-00006

Weitere Artikel der Ausgabe 18/2006

Drugs 18/2006 Zur Ausgabe

Adis Drug Profile

Fentanyl Buccal Tablet